EndoC-βH1 cell line, Homo sapiens treated with 50 U/mL Interleukin-1 beta for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 1000 U/mL Tumor necrosis factor for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 2 μM dexamethasone for 86400 seconds, grown in DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg CVB4-JVB for 3600 seconds, grown in OPTIβ1 medium

EndoC-βH1 cell line, Homo sapiens grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 28800 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg STAT3 siRNA for 0 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 7200 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS2 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-βH1 cell line, Homo sapiens treated with 1000 U/mL Interferon gamma for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-βH1 cell line, Homo sapiens grown in OPTIβ1 medium

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg CVB4-E2 for 3600 seconds, grown in OPTIβ1 medium

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS1 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS3 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg Negative control siRNA for 0 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 86400 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin